Further analyses are warranted to generally understand if the BW reduction is greater in participants with low eGFR in this T2D population at high risk of CVD
You can do the same
doi: 10.1016/j.jaut.2017.06.001 133 MoltchanovaEVSchreierNLammiNKarvonenM
Now, 68% of users are taking GLP-1s specifically to lose weight, opening them up to a much wider audience." The findings, based on responses from more than 11,500 households, suggest that these medications becoming more popular has had significant implications for food and drink manufacturers, retailers and foodservice operators
These findings suggest a role for bacterial products, perhaps of lung origin, in augmenting the production of inflammatory cytokines in severe COVID-19
At GLP-1R, it stimulates insulin secretion, suppresses glucagon, and slows gastric emptying